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HSP90 is a molecular chaperone that associates
with numerous substrate proteins called clients. It
plays many important roles in human biology and
medicine, but determinants of client recognition
by HSP90 have remained frustratingly elusive. We
systematically and quantitatively surveyed most
human kinases, transcription factors, and E3 ligases
for interaction with HSP90 and its cochaperone
CDC37. Unexpectedly, many more kinases than
transcription factors bound HSP90. CDC37 inter-
acted with kinases, but not with transcription factors
or E3 ligases. HSP90::kinase interactions varied
continuously over a 100-fold range and provided a
platform to study client protein recognition. In wild-
type clients, HSP90 did not bind particular sequence
motifs, but rather associated with intrinsically un-
stable kinases. Stabilization of the kinase in either
its active or inactive conformation with diverse small
molecules decreasedHSP90 association. Our results
establishHSP90 client recognition as a combinatorial
process: CDC37 provides recognition of the kinase
family, whereas thermodynamic parameters deter-
mine client binding within the family.INTRODUCTION
HSP90 is one of the most abundant chaperone proteins in the
cell. It interacts with a large and diverse group of substrate
proteins, commonly referred to as ‘‘clients,’’ promoting their
folding and function. HSP90 seems to be focused onmetastable
proteins that are regulatory hubs in biological networks. This
makes HSP90 a driving force in the evolution of new forms and
functions in organisms as diverse as yeast, fruit flies, and thale
cress. Recent work has established the importance of HSP90
in many aspects of human biology, ranging from cancer to infec-tious diseases to neurodegeneration (Taipale et al., 2010). Iden-
tifying the full spectrum of HSP90 client proteins has, therefore,
gained increased urgency. So, too, has the need to determine
the mechanistic basis of HSP90 client protein interactions.
In contrast to Hsp70 and Hsp60 chaperones, for which the
mechanism of client protein recognition is understood in general
terms, we still have only a rudimentary understanding of what
determines client protein binding by HSP90. Three features
of HSP90 client interactions illustrate the complexity of the
problem: the perplexing diversity of Hsp90 clients, the meta-
stable character of their folds, and the complexity of its chap-
erone cycle. First, HSP90 clients encompass a wide range of
proteins with unrelated amino acid sequences and functions,
including protein kinases and steroid hormone receptors (Tai-
pale et al., 2010). Although the kinase domain and the ligand-
binding domain of steroid hormone receptors are structurally
unrelated, these domains must have specific sequence or struc-
tural features that HSP90 recognizes. Second, in each client
protein family some members robustly interact with the chap-
erone, while others apparently do not associate with it at all.
For example, mature epidermal growth factor receptor (EGFR)
does not associate with HSP90, whereas its closest homolog,
ERBB2, tightly interacts with it (Xu et al., 2005). Thus, despite
the overall conservation of the protein fold, there must be
specific sequence or structural features that distinguish client
proteins from nonclients. Finally, HSP90 associates with a large
cohort of auxiliary proteins, known as cochaperones, which
regulate its function and seem to provide specificity to client
protein interactions. Yet, the role and specificity of cochaper-
ones in client protein recognition is not well understood.
Previous work on steroid hormone receptors and kinases has
suggested some features that could determine HSP90 client
protein associations (Ricketson et al., 2007; Xu et al., 2005). For
some kinases, mutations in the loop between aC helix and b4
strand in the N-lobe of the kinase domain have strong effects on
HSP90 binding, leading to the hypothesis that the aC-b4 loop is
the HSP90 recognition site (Citri et al., 2006; Xu et al., 2005). Yet,
a survey of known HSP90 client kinases and nonclients did not
uncover client-specific sequence motifs in the loop (Citri et al.,
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clients) associate with HSP90 because the chaperone recognizes
something related to their conformational instability, but the data
are insufficient to reach any unifying conclusions and reconcile
diverse observations (Caplan et al., 2007; Taipale et al., 2010).
A quantitative high-throughput assessment of HSP90 client
interactions could transform our understanding of these issues
but has proved challenging for several reasons. First, HSP90’s
interactions with its clients are transient and might not be de-
tected by standard interaction assays that require the formation
of stable complexes. Second, binary assays, such as yeast two-
hybrid assays, may not recapitulate all HSP90 interactions in
human cells due to the absence of correct cochaperones or
posttranslational modifications. Third, client proteins tend to be
expressed at very low levels. Consequently, methods based
on mass spectrometry have primarily revealed chaperone::
cochaperone interactions; only a handful of bona fide client
proteins have been found by this method (Falsone et al., 2005,
2007). Finally, most assays do not allow relative quantification
of interactions with HSP90.
To circumvent these limitations, we adapted and further devel-
oped the LUMIER assay (Barrios-Rodiles et al., 2005) to system-
atically measure HSP90 interaction with the majority of human
protein kinases, transcription factors and ubiquitin ligases in vivo.
Surprisingly, HSP90 bound only 7% of transcription factors,
but 30% of ubiquitin ligases and 60% of kinases. The conserved
nature of the kinase fold, together with the sheer numbers of
clients, then provided a robust platform to address client protein
features that determine interaction with HSP90. In addition to
providing a comprehensive view of the HSP90::kinase interac-
tome, our results reveal two principles of HSP90 client interac-
tions. A cochaperone provides recognition of particular types
of fold, whereas thermal and conformational stability determines
the extent of interaction.
RESULTS
Quantitative Measurement of Protein-Protein
Interactions In Vivo by LUMIER with BACON
In the LUMIER assay, one test protein (bait) is tagged with
a FLAG tag and the other (prey) is tagged with Renilla luciferase
(Barrios-Rodiles et al., 2005). Proteins are transiently coex-
pressed in mammalian cells by transfection, and cell lysates
are applied to 96-well plates containing anti-FLAG-coated
beads. Interaction of bait and prey proteins is detected by lumi-
nescence after immunoprecipitation. We improved the original
LUMIER assay to make it more quantitative and to increase its
throughput. For example, we used a stable 293T cell line ex-
pressing the luciferase-tagged prey protein to minimize well-
to-well variation. We also introduced a step that controls for
bait abundance: after reading luminescence (i.e., prey abun-
dance), the abundance of the 3 3 FLAG -tagged bait is
measured with ELISA, using a different, polyclonal antibody
against the FLAG tag (Figure 1A). We named the modified assay
LUMIER with bait control (LUMIER with BACON).
HSP90::Client Interaction Assay
We collected 420 ORF clones representing 355 unique protein
kinases and their variants (69% of the human kinome), 1,303988 Cell 150, 987–1001, August 31, 2012 ª2012 Elsevier Inc.transcription factor (TF) clones (1,093 unique TFs/79% of all),
and 498 E3 ligase clones (426 unique; 69% of all). These
were transferred into an expression vector with a C-terminal
3 3 FLAG-V5 tag. We then created a stable cell line expressing
codon-optimized Renilla luciferase fused to the HSP90b N
terminus, based on earlier observations that N-terminal tagging
of HSP90 does not significantly affect its function (Boulon
et al., 2010). The tagged HSP90b protein was expressed at
less than 10% of the endogenous HSP90b (data not shown)
and should therefore not significantly affect client interactions.
Renilla-Hsp90 cells were transfected with bait constructs in
96-well format. Cells were lysed 48 hr later and the lysates were
applied to anti-FLAG-coated 384-well plates. After incubation
and copious, but very rapid washes, luminescence in each well
provided a measure of how much HSP90 had been captured.
Immediately thereafter, ELISA was used to quantify bait protein
abundance. To establish a robust cutoff for true interactions,
we tested 176 kinases for interaction withRenilla luciferase itself,
using a stable cell line expressing just the luciferase. We set
a cutoff for true interactions such that at least 99.5% of non-
specific interactions were excluded (i.e., all 176 kinase::Renilla
luciferase interactions fell below the cutoff; Figure 1B).
Altogether, 314 of the kinases were expressed at levels
detectable by ELISA, and of those, 193 (61%) passed the criteria
for true interaction (Figure 1B; Table S1 available online).
Therefore, HSP90 associates with more than half of the human
kinome. We calculated a quantitative interaction score (log2
[HSP90]/[kinase]) for the 193 kinases that interacted with
HSP90 (Figure 1C). These scores were highly reproducible
(R2 = 0.95) and covered more than a 100-fold range of HSP90/
kinase ratios, illustrating that steady-state HSP90 association
with client proteins varies over a continuum. Thus, the commonly
used binary classification of kinases as HSP90 clients or non-
clients does not at all capture the breadth of HSP90::substrate
interactions in the cellular context. However, to simplify down-
stream analysis, we divided kinases into three classes based
on the LUMIER interaction score. Kinases with an interaction
score above 3 (n = 98) were classified as ‘‘strong’’ clients and
those with an interaction score below 3 (n = 95) as ‘‘weak’’
clients. The rest (n = 121) were classified as nonclients.
To assess the quality of our data set, we validated the interac-
tion of ten FLAG-tagged kinases from each class with endoge-
nous HSP90 by conventional coimmunoprecipitation. All strong
and weak interactions were reproduced (Figure S1A). Further-
more, confirming the quantitative nature of the LUMIER assay,
strong clients indeed interacted more strongly with endogenous
HSP90 than weak clients did. Only two of the ten kinases we
classified as nonclients interacted with endogenous HSP90,
and both interactions were extremely weak (Figure S1A). Thus,
the LUMIER data set contains high-confidence kinase clients
(true positives), but this does not lead to a large number of true
clients classified as nonclients (false negatives).
Finally, because HSP90::client interactions are transient
in vivo, it was important to ensure that we did not lose such asso-
ciations during the washing steps. All tested interactions were
abolished when cells were treated for 1 hr with 500 nM ganetes-
pib, a potent HSP90 inhibitor (Ying et al., 2011). However, gane-
tespib had only a very marginal effect on HSP90::kinase
Figure 1. LUMIER with BACON Assay Reveals the Quantitative Nature of HSP90::Client Interactions
(A) Principle of the assay. 3 3 FLAG-tagged bait constructs (putative HSP90 clients) are transfected into a 293T cell line stably expressing Renilla luciferase-
tagged HSP90 (prey). Cell lysates are incubated in 384-well plates coated with anti-FLAG antibody. After washing off nonspecific proteins, luminescence is
measured. Interaction of HSP90 with the bait can be detected as luminescence. In the second step, the amount of bait is measured with anti-FLAG ELISA. The
log2 ratio between bait and prey concentration is the interaction score.
(B) Distribution of luminescence in HSP90 interaction assays with 420 kinase clones (red), 498 E3 ligase clones (green), and 1,093 transcription factor clones
(blue). As a control, 176 kinase clones were tested against a cell line expressing Renilla luciferase only (black). Gaussian curve was fitted to each data set to
establish a cutoff for true interactions (dashed black line).
(C) Quantitative interaction score was calculated for all 193 kinases that interacted with HSP90. Scatter plot shows the interaction scores from two biological
replicates.
See also Figure S1 and Table S1.
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interactions when added after lysis, even at a 20-fold higher
concentration (Figure S1B). These results establish that interac-
tions captured by LUMIER are true chaperone::client interac-
tions and that these interactions are stable in the assay
conditions.
Few Transcription Factors, but Many E3 Ligases,
Interact with HSP90
In stark contrast to kinases, less than 7% (58 of 843 unique TFs
detectable by ELISA) of human transcription factors (Figure 1B;
Table S1) interacted with HSP90. The low number of TF clients
is surprising, since it is commonly thought that TFs represent a
substantial fraction of HSP90 clients (Taipale et al., 2010). Based
on our results, it appears that steroid hormone receptors, a previ-
ously well-established class of HSP90 clients, actually constitute
an exceptional TF family with respect to HSP90 binding. Among
ubiquitin ligases, 31% (117/372) interacted with HSP90 (Fig-
ure 1B; Table S1). Interestingly, most E3 ligases with Kelch or
WD40 domains interacted with HSP90. This trend was highly
significant (Kelch: 19 interactors out of 32 proteins, p < 0.0004;
WD40: 8/11, p < 0.0055, Fisher’s exact test). Thus, beta-pro-
peller domains such as Kelch and WD40 may comprise a novel
HSP90 client protein fold. Furthermore, all of the Cullin scaffold
proteins we tested (Cul1, Cul2, Cul3, Cul4B, Cul4A) interacted
with HSP90 except for Cul4B. Previously, Cul5 was shown to
interact with HSP90 and regulate client protein degradation (Ehr-
lich et al., 2009). Our results suggest that other Cullins may also
regulate the proteasomal degradation of client proteins.
Kinase Specificity of HSP90 Is Provided by CDC37
To addresswhat determines HSP90 binding at the protein-family
level, we analyzed an HSP90 cochaperone, CDC37, known to
associate with many kinases (Grammatikakis et al., 1999; Gray
et al., 2008). It is not known, however, whether CDC37 is
a universal kinase cochaperone or whether it is strictly kinase
specific. We constructed a cell line stably expressing CDC37
that was C-terminally tagged with Renilla luciferase to assess
interactions between CDC37 and each of the kinases, TFs, and
E3 ligases that we had tested for interaction with HSP90. Similar
to HSP90, CDC37 interacted with the majority of kinases. More-
over, HSP90::kinase and CDC37::kinase interaction profiles
correlated strongly (R2 = 0.81; Figure 2A). In contrast, CDC37 in-
teracted with only 3.3% of TFs (24/720) and 1.3% (5/375) of E3
ligases, and the correlation between HSP90 and CDC37 interac-
tions within these two protein classes was negligible (Figures 2B
and 2C; Table S1).
These data strongly suggested that CDC37 serves as an
adaptor for the kinase fold. To investigate more rigorously, we
reduced CDC37 levels with shRNA-mediated knockdown. This
had no effect on HSP90 levels (Figure 2D). However, almost all
tested kinase::HSP90 interactions were reduced after CDC37
knockdown, whereas nonkinase clients still interacted with
HSP90, as measured by LUMIER (p < 0.0001; Figure 2E). Next,
we tested 17 kinase::HSP90 interactions by conventional coim-
munoprecipitation. Fifteen of these interactions were signifi-
cantly reduced after CDC37 knockdown, while none of the seven
nonkinase client interactions we tested were affected (Figure 2F;
data not shown).990 Cell 150, 987–1001, August 31, 2012 ª2012 Elsevier Inc.Taken together, these data establish that CDC37 is a
highly specialized cochaperone adaptor for kinases. Further,
the remarkably strong correlation between HSP90::kinase and
CDC37::kinase interactions demonstrates that HSP90 and
CDC37 act in concert in chaperoning client kinases. Thus, the
adaptor function of CDC37 explains the family-level specificity
of HSP90::kinase interactions.
Inhibition of HSP90 Leads to Dissociation of Most
HSP90::Kinase Complexes
Next, we took advantage of the large number of HSP90 kinase
clients, all having the same kinase fold, to globally assess the
consequences of client protein::HSP90 associations and to
investigate why some highly related members of a protein family
bind HSP90 while others do not. We first tested eight HSP90
inhibitors based on several different chemical scaffolds for their
ability to disrupt the HSP90::ARAF complex. All the inhibitors
dissociated ARAF fromHSP90with a 1 hr treatment (Figure S2A).
The most potent inhibitor was ganetespib with an IC50 of 26 nM
(Figure S2B); therefore, we used it in all subsequent assays.
We measured each kinase::HSP90 interaction after treating
cells for 1 hr with 500 nM ganetespib or with DMSO. We also
tested the effect of ganetespib on HSP90’s interaction with
CDC37 and on HSP90b homodimerization, to distinguish cli-
ent::chaperone interactions from interactions within the chap-
erone machinery itself. Neither CDC37::HSP90b interactions
nor HSP90b::HSP90b dimerization was affected by ganetespib.
In contrast, almost all HSP90::kinase interactions were abol-
ished or significantly decreased (Figure 3A).
The extent of dissociation from HSP90 did vary, however. For
example, CDK10, GSG2, and CSNK1E did not dissociate and
FGFR3 dissociated only partially (Figure 3A). We confirmed
these results by conventional coimmunoprecipitation (Fig-
ure S2C). Next, we used LUMIER to ask if these kinases
increased the IC50 of ganetespib for HSP90 or whether they
simply have a slower dissociation rate. The IC50 of ganetespib
for STK38, CDK6, LCK, and FGFR3 complexes with HSP90
was at the low nanomolar range (15–30 nM; Figures S2D and
S2F) similar to that of the ARAF::HSP90 complex. With this
more detailed analysis, we also observed partial dissociation
of CDK10 and GSG2 from HSP90 with low nanomolar IC50
(Figure S2D).
In contrast to the highly similar IC50 values, there were marked
differences in dissociation rates. After treating the cells with
500 nM ganetespib, STK38, CDK6, and LCK (Figure S2C)
dissociated from HSP90 with a half-life of 3 min (Figure S2E).
Another 15 kinases we tested had similar dissociation rates
(2–6 min; data not shown). In contrast, FGFR3 dissociated with
a T1/2 of 29 min. Dissociation of CDK10, GSG2, and CSNK1E
showed yet a different pattern. Their dissociation rates were
somewhat slower than for most kinases, but more significantly,
they only partially dissociated from HSP90 even after prolonged
inhibitor treatment (Figure S2E).
Thus, exceptions show that the chaperone cycle for a few
kinases, such as FGFR3, is significantly slower than that for
most kinases. Furthermore, partial dissociation of other kinases
such as CDK10 and GSG2 suggest that these kinase-HSP90
complexes represent two different pools, only one of which is
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Figure 2. CDC37 Is a Universal Kinase-Specific Cochaperone
(A–C) HSP90 interaction profiles were compared with CDC37 interaction profiles for kinases (A), transcription factors (B), and E3 ligases (C). Plots show mode-
normalized, log2-transformed luminescence values.
(D) 293T cells were infected with a lentivirus expressing an shRNA construct targeting Cdc37 or GFP.
(E) CDC37 is required for kinase::HSP90 interactions. Client proteins were transfected in duplicate into Renilla-HSP90 expressing cells infected with either Cdc37
or GFP shRNA. Forty-eight hours after transfection, interaction with each client was measured with LUMIER. Boxes indicate 25th and 75th percentiles and
whiskers 10th and 90th percentiles. p value was calculated with Wilcoxon rank sum test. (F) 3 3 FLAG-tagged client proteins were transfected into 293T cells
infected with either Cdc37 or GFP shRNA. Forty-eight hours later, clients were immunoprecipitated with an anti-FLAG antibody. Coimmunoprecipitation with
endogenous HSP90 was assayed with a monoclonal HSP90 antibody.
See also Figure S1.sensitive to HSP90 inhibition. However, the vast majority of
HSP90::client kinase interactions had similar sensitivities to
disruption of the chaperone cycle, with remarkably similar
IC50s for HSP90 inhibitors and very similar HSP90 off-rates.The Fate of KinaseClients Varies after Inhibitor-Induced
Dissociation
Next, we tested the effect of HSP90 inhibition on the cellular fate
of client proteins. We transfected 3 3 FLAG-tagged kinases inCell 150, 987–1001, August 31, 2012 ª2012 Elsevier Inc. 991
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Figure 3. An HSP90 Inhibitor Induces Disso-
ciation of Most HSP90::Kinase Complexes,
but HSP90 Interaction Strength Correlates
Poorly with Subsequent Degradation
(A) HSP90::kinase interactions were measured
after treating cells with 500 nM ganetespib or
vehicle for 1 hr before cell lysis and LUMIER assay.
HSP90b::CDC37 interaction (blue) and HSP90b
homodimerization (green) is not affected by ga-
netespib. Dashed black line indicates no change in
HSP90 interaction upon ganetespib treatment.
Kinase clonesmarked with filled black circles were
further validated with coimmunoprecipitation with
endogenous HSP90 (Figure S2).
(B) Ganetespib-induced degradation of client
kinases correlates poorly with HSP90 interaction
score. 33 FLAG-tagged kinases were transfected
into 293T cells, which were subsequently treated
with 100 nM ganetespib or vehicle for 20 hr.
Protein levels were measured with anti-FLAG
ELISA. Relative protein level is plotted against
Hsp90 interaction score from LUMIER assay.
(C) HSP90 inhibition can lead to either degradation
or aggregation of strong client proteins. Left panel:
3 3 FLAG-tagged kinases were transfected into
293T cells, which were treated with 100 nM ga-
netespib for indicated times. Protein levels were
measured with an anti-FLAG antibody. Right
panel: 33 FLAG-tagged kinases were transfected
into 293T cells, and after 24 hr treatment with
100 nM ganetespib or vehicle, the soluble fraction
(0.1% Triton) was separated from the insoluble
fraction. Protein levels were measured with an
anti-FLAG antibody.
(D) Degradation or aggregation of weak client
proteins after HSP90 inhibition. Experiment was
performed as in (C) but with weak HSP90 client
proteins.96-well format into 293T cells and, 24 hr after transfection,
added 100 nM ganetespib or DMSO. After a further 20 hr incuba-
tion, cells were lysed and relative protein abundance measured
with an anti-FLAG ELISA. As a control, we used c-Src, which is
insensitive to HSP90 inhibition, and oncogenic v-Src, which is
exquisitely sensitive (Xu et al., 1999).
Protein levels could be confidently assessed for 291 kinases
with good reproducibility (Figure S2G). As expected, v-Src
was almost completely degraded after ganetespib treatment
and c-Src was only modestly affected (Figure S2G). On average,
strong clients were degraded to a greater extent after gane-
tespib treatment (p < 0.01) than weak clients. In turn, weak
clients were degraded more than nonclients (p < 0.0001)
(Figure S2H). However, the correlation between HSP90 inter-
action and ganetespib-induced degradation was surprisingly
weak (R2 = 0.15, p < 0.0001; Figure 3B). A number of strong992 Cell 150, 987–1001, August 31, 2012 ª2012 Elsevier Inc.client kinases were not efficiently
degraded even though they were effi-
ciently dissociated from HSP90 by the
inhibitor (Figure S2I). We further validated
these results by western blotting (Figures
3C and 3D).Next, for kinases that dissociated from HSP90 without being
degraded, we asked if dissociation led to aggregation. After
the same incubations described above, the soluble fraction
(0.1% Triton X-100) was separated from the insoluble fraction.
Indeed, kinases that were poorly degraded upon HSP90
inhibition accumulated in the insoluble fraction, presumably
because they aggregated (Figures 3C and 3D, right panel).
Thus, HSP90 inhibition very broadly affects the fate of its client
proteins. The balance between aggregation and degradation
varies with each client, however.
Determinants for HSP90 Association Are Complex
and Widely Distributed
To investigate why some normal cellular kinases interact with
HSP90 and others do not, we first plotted interaction scores on
the phylogenetic tree of human kinase domains (Manning
et al., 2002) (Figure 4). Strikingly, each major kinase branch had
both clients and nonclients and, even on different branches, the
clients did not cluster. Furthermore, kinases with strong interac-
tion scores often had very close relatives that did not interact.
The LUMIER assay detected previously reported differences
between HSP90’s interaction with EGFR and ERBB2 (nonclient
versus weak client; Xu et al., 2005), and between ARAF and
BRAF (strong client versus weak client; da Rocha Dias et al.,
2005). It also uncovered many other, similarly discordant pairs.
For example, transforming growth factor (TGF)-b receptor
ACVR1B/ALK4 was a strong client protein, whereas its closest
homolog, TGFBR1/ALK5 did not bind HSP90, despite sharing
95% aa similarity over the kinase domain (Figure S3A). The
Csk-type protein kinase CTK/MATKwas a strong client, whereas
CSK, with 77% aa similarity in the kinase domain, did not bind
HSP90 at all. All of these differences were validated directly
with coimmunoprecipitation (Figure S3A, lower panel). Thus,
HSP90 specificity is not determined by the evolutionary history
of the kinase.
Several studies have tried to identify regions in the kinase
domain that might explain why some kinases associate with
HSP90 whereas others do not (Citri et al., 2006; Xu et al.,
2005). No consensus motifs have emerged from the limited
number of kinases studied, but our comprehensive data set
provides unprecedented opportunity to search for them. We
used mutual information analysis, OMES covariance, SCA
covariance, and McBasc (Fodor and Aldrich, 2004) to identify
residues that might covary with HSP90 binding status. We
created a multiple alignment of all kinase domains, manually
refining the alignment where appropriate. Loops were excluded
from the analysis due to poor alignment confidence, and weak
clients were excluded to eliminate ambiguity.
Nine residues significantly (p < 0.01) covaried with HSP90
interaction status using all algorithms (Figure S3B). Interestingly,
six of the covarying residues were located in the long aE helix of
the kinase C-lobe (Figure S3C). Two of these (residues 147 and
151, numbering with reference to protein kinase A) face the
hydrophobic core of the C-lobe, and were more hydrophobic
in nonclient kinases than in clients, which preferred alanine in
these positions (Figure S3B). The neighboring residue 153 is
usually a glycine or alanine in kinases. In strong clients, the
distribution was significantly biased toward glycine, whereas
nonclients had an alanine more frequently in this position. We
separately analyzed weak clients and found them to have an
intermediate bias in all these residues (Figure S3B). Alanine
has the strongest propensity to form a helices, whereas glycine
is, after proline, the least favored amino acid in a helices (Pace
and Scholtz, 1998). Thus, weaker hydrophobic packing and
destabilization of the aE helix by glycine might explain some of
the observed differences between nonclients and clients.
However, the differences in covarying residues between
clients and nonclients were, at best, modest and could explain
only a small fraction of variation in HSP90 client status. This
was corroborated by the fact that most of the closely related
kinase pairs that had discordant HSP90 interaction scores had
identical or nearly identical residues in covarying positions of
the aE helix. Thus, themajor determinants for HSP90must reside
in other features of these kinases.Determinants for HSP90 Association Can Be Widely
Distributed
To investigate binding determinants, we focused on the three
RAF family kinases, ARAF, CRAF, and BRAF, because they are
highly similar over the kinase domain, yet the difference in their
association with HSP90 was extreme. Of the 314 kinases we
tested, ARAF was the sixth strongest interactor and CRAF was
the 11th strongest, whereas the binding of BRAF was barely
detectable. First, we created several chimeric constructs to vali-
date that the HSP90 binding determinants are located in the
kinase domain (Figure S4A). Chimeric proteins containing the
regulatory domain or the C-terminal tail of BRAF but the ARAF
kinase domain interacted strongly with HSP90. Reciprocally
swapped constructs did not (Figure 5A, blue bars).
Next, we mutated each residue in the BRAF kinase domain
that was different from the corresponding residues in both
ARAF and CRAF (Figure S4B). In total, 25 mutant constructs
were tested. Strikingly, no single mutation conferred robust
HSP90 association for BRAF (Figure 5A, green bars). In contrast,
ARAF and BRAF kinase domain chimeras, in which the N-lobe of
one kinase was fused to the C-lobe of the other kinase domain,
resulted in intermediate binding for both (Figure 5A). These
results establish that HSP90 binding determinants in these
wild-type proteins are widely distributed in both lobes of the
kinase domain and act to determine HSP90 interaction in
a combinatorial way.
HSP90 Association Can Also Be Modulated by Highly
Localized Elements
Results with RAF family proteins, as well as amino acid residue
covariation analysis, suggest that a distributed set of residues
is required for robust HSP90 association. To our surprise,
however, we also found that alternative splice isoforms of the
very same kinase sometimes had striking differences in HSP90
binding. For example, the AMP-activated kinase AMPKa1 had
two alternative splice isoforms in our library. The longer contains
an additional exon that adds 15 amino acids to the aD-aE loop in
the kinase C-lobe (Figure 5B). This isoform strongly associated
with HSP90; the shorter isoform did not. The closely related
AMPKa2 isoform, encoded by a distinct gene and sharing 96%
amino acid similarity over the kinase domain, does not contain
a long loop and is not an HSP90 client.
These data would seem to indicate that the aD-aE loop
contains a sequence that determines HSP90 association, but
this proved not to be the case. We first confirmed the LUMIER
finding by immunoprecipitation with the endogenous HSP90
protein (Figure 5C). Next, we constructed and analyzed new vari-
ants of the AMPKa1 paralog AMPKa2. Inserting the 15 aa
sequence from AMPKa1 into the same position on AMPKa2
significantly increased its association with HSP90 (Figure 5C).
However, insertion of the same DNA sequence but inverted
and encoding an unrelated amino acid sequence, similarly
increased HSP90 binding. Finally, we inserted these same loops
into CDK2, a nonclient from a different kinase family. Again,
longer aD-aE loop promoted HSP90 association regardless of
the loop sequence. Thus, the mere presence of a long aD-aE
loop, regardless of the amino acid sequence, can drastically
affect HSP90 association.Cell 150, 987–1001, August 31, 2012 ª2012 Elsevier Inc. 993
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Figure 5. HSP90 Interaction Is Determined
by a Distributed Set of Residues and Is
Affected by Alternative Splicing
(A) Multiple residues regulate ARAF interactionwith
HSP90. 3 3 FLAG-tagged kinase constructs were
transfected into Renilla-HSP90 cells and their
interaction with HSP90 was measured with LU-
MIER. Wild-type BRAF interacts weakly with
HSP90, whereas RAF1 (CRAF) and ARAF are
among the strongest HSP90 clients (gray).
Constructs containing the kinase domain of ARAF
but regulatory domains of BRAF interact strongly
with HSP90 (blue), but single point mutations in
BRAF do not confer robust interaction with HSP90
(green). Clones with chimeric kinase domains
display intermediate phenotypes (orange). Error
bars indicate SDs (n = 4).
(B) Location and the sequence of the alternatively
spliced aD-aE loop in AMPKa1 (PRKAA1) are
shown in the structure of theAMPKa2 isoform (PDB
2H6D). Kinase N-lobe is colored blue, C-lobe in
green, aD helix in red, and aE helix in salmon pink.
(C) Alternative splicing of AMPKa1 regulates
HSP90 association. 3 3 FLAG-tagged kinase
constructs were transfected into 293T cells and
interaction with endogenous HSP90 was assayed
by coimmunoprecipitation. AMPKa1 loop was in-
serted into AMPKa2 or CDK2 that do not have
loops between the two helices. As a control, the
DNA sequence encoding the loop sequence was
also inserted inverted (inv) into the same location.
See also Figure S4.Similarly, we found that alternative splicing of the GRK6 kinase
regulated its association with HSP90 in a sequence-independent
manner (Figures S4C and S4D).
HSP90 Client Kinases Are Intrinsically Less Stable
Our findings presented a paradox. While determinants for
HSP90 interaction can be widely distributed, alternative splicing
can produce highly localized changes with marked effects. How
might these results be reconciled? To address this question, we
globally analyzed the general properties of each class of kinases.
Client and nonclient kinases had similar subcellular localizations.
Strong clients and nonclients had no difference in hydropho-
bicity. Nonclient proteins were, on average, smaller than weak
or strong clients but this difference was slight and not significantFigure 4. HSP90 Associates with the Majority of the Human Kinome
Quantitative HSP90 interaction scores are plotted on the human kinome tree (courtesy of Cell Signaling Tech
divided into eight bins and color coded. Client proteins were further divided into weak clients (interaction scor
left, distribution of clients within kinase families. Tyrosine kinases are the only family that contains more client
value 0.027, Wilcoxon rank sum test). Kinase tree from Manning et al. (2002). Reprinted with permission from
Science (AAAS).
See also Figure S3.
Cell 150, 987–100when only kinase domains were con-
sidered (data not shown). Somewhat
more surprisingly, given the importance
of HSP90 in protein homeostasis net-
works, clients and nonclients had similarnumbers of interaction partners and, moreover, did not differ in
the number or the length of intrinsically disordered regions (Table
S1; data not shown). Given the role of Hsp90 in evolutionary
processes, however, it is notable that the amino acid sequences
of the client kinases have evolved more quickly than those of
nonclients (Figure S5A).
Suggesting HSP90 clients might be less stable than non-
clients, fewer clients had a solved crystal structure for the kinase
domain deposited in the Protein Database (p = 0.0012, Fisher’s
exact test; Figure 6A). (There was no publication bias between
the kinase classes (Table S1), excluding the trivial explanation
of research priorities.) To corroborate this finding, we analyzed
protein expression data from the Structural Genomics Consor-
tium (SGC) (kindly provided by Stefan Knapp). In their efforts tonologies and Science Magazine). Interactions were
e 1–3) or strong clients (interaction score 4–7). Inset
s than expected by chance (Bonferroni-corrected p
the American Association for the Advancement of
1, August 31, 2012 ª2012 Elsevier Inc. 995
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Figure 6. HSP90 Associates with Thermo-
dynamically Unstable Kinases
(A) Distribution of kinase domain crystal structures
deposited to PDB by client class and expression
system extracted from the PDB coordinate file. p
value was calculated with Fisher’s exact test.
(B) Strong HSP90 clients are less soluble than
nonclients or weak clients. Kinase domains that
have been expressed in a soluble manner by
Structural Genomics Consortium are divided into
client classes. p value was calculated with Fisher’s
exact test.
(C) ATP-competitive inhibitors decrease HSP90::
BCR-ABL interactions. 3 3 FLAG-tagged kinases
were transfected into Renilla-HSP90 cells, and
HSP90 interaction was measured by LUMIER
after 1 hr treatment with 5 mM inhibitor or
DMSO. Average relative interaction with HSP90
(DMSO = 1) from four independent replicates is
shownwith SD. Statistical significance is shown as
asterisks (*p < 0.05; ***p < 0.001).
(D) Stabilization of the kinase fold with allosteric
modulators decreases HSP90::BCR-ABL interac-
tions. Experiment was done as in Figure 5C, using
5 mM GNF-2 or DPH.
(E) BCR-ABL point mutations have opposing
effects on HSP90 interaction. Interaction of wild-
type BCR-ABL (black), M472I mutant (blue) and
M244I mutant (red) with HSP90 was measured
with LUMIER. Average relative interaction (wild-
type = 1) from four independent replicates is
shown with standard deviation.
(F) Thermal stability of ABLmutants correlates with
HSP90 association. Thermal denaturation curves
of wild-type ABL and M472I and M244I mutant
proteins were determined by circular dichroism.
See also Figure S5.determine the three-dimensional structure of every kinase in
the human genome, SGC has expressed a large number of
human kinase domains in heterologous expression systems.
They have successfully expressed, as determined by protein
solubility, 163 human kinase domains. Soluble protein was996 Cell 150, 987–1001, August 31, 2012 ª2012 Elsevier Inc.obtained for 36% of all nonclients but
for only 16% of strong clients (p =
0.0005, Fisher’s exact test; Figure 6B).
Importantly, neither of these differences
was significant for kinases that had been
expressed in eukaryotic systems. This is
consistent with known differences in
the HSP90 machinery of prokaryotic and
eukaryotic cells—prokaryotes do not
have CDC37 and the prokaryotic HSP90
does not chaperone kinases (Buchner,
2010)—as well as with our observation
that CDC37 is universally employed by
HSP90 for all kinases.
Low solubility in vivo can be caused
by multiple mechanisms—electrostatics,
aggregation propensity, conformational
(kinetic) instability or thermal instability.To further evaluate biophysical differences between nonclient
and client kinases, we compared HSP90 interaction profiles
with 56 published in vitro thermal stability profiles for kinase
domains (Fedorov et al., 2007). Our quantitative interaction
scores for Hsp90 clients correlated with thermal instability
(R2 = 0.23, p = 0.019; Figure S5B). The correlation between these
very different types of assays (in vivo full-length kinases versus
in vitro kinase domains) is all the more striking considering that
most of the successfully purified proteins were nonclients (and
are therefore not plotted on this graph). Only three measure-
ments were available from moderately strong clients (LUMIER
interaction scores of 3–4) and none from very strong clients
(interaction scores 5–7). Notably, an independent analysis of
mutated oncogenic v-Src (which scored as a strong client in
our assay) established that it was much less stable in vitro than
c-Src (Falsone et al., 2004), a nonclient.
Stabilization of the Kinase Domain by Small Molecules
Decreases HSP90 Association
If HSP90 association is determined by the intrinsic stability of the
kinase domain, it should be possible to alter HSP90::kinase
interactions with stabilizing factors. To test this, we focused
on BCR-ABL. A number of potent small-molecule inhibitors, of
distinct chemotypes and with different modes of binding,
have been developed against BCR-ABL. The binding of such
inhibitors increases the stability of kinase domains in vitro
(Fedorov et al., 2007).
First, we tested the effects of imatinib (Gleevec) and dasatinib
(Sprycel). Both inhibit BCR-ABL very potently and bind the ATP
binding pocket in an ATP-competitive manner. When these
two inhibitors bind BCR-ABL, however, they stabilize distinct
conformations. Imatinib binds the inactive conformation and
dasatinib the active one. Both inhibitors significantly decreased
HSP90::BCR-ABL interaction (Figure 6C). As a control, interac-
tion between HSP90 and FLT4, a tyrosine kinase not targeted
by imatinib, was not affected by the drug. Next we tested the
clinically relevant imatinib-resistant BCR-ABL mutation T315I,
which blocks the binding of both inhibitors to the ATP-binding
site. The mutation abolished the effect of both inhibitors on
HSP90 binding.
To address the possibility that HSP90 and the small-molecule
inhibitors simply compete for binding to the ATP-binding pocket,
we used GNF-2. This molecule is an allosteric Abl inhibitor that
binds a unique myristate-binding pocket in the C-lobe far away
from the ATP binding site (Adria´n et al., 2006). Similar to imatinib
and dasatinib, GNF-2 significantly decreased BCR-ABL::HSP90
interaction but had no effect on the FLT4::HSP90 complex (Fig-
ure 6D). However, in striking contrast to the ATP-competitive
inhibitors, GNF-2 also decreased the interaction between the
BCR-ABL T315I mutant and HSP90. This is consistent with the
observation that this class of inhibitors binds to both the wild-
type and the T315I mutant protein (Iacob et al., 2011).
Finally, we asked if the decrease in HSP90’s interaction with
BCR-ABL might simply be the result of reduced kinase activity.
DPH, another small-molecule modulator of ABL function, binds
the same allosteric pocket as GNF-2 but activates the kinase
rather than inhibiting it (Yang et al., 2011). The effect of DPH on
the HSP90::BCR-ABL interaction was identical to that of
GNF-2: both native BCR-ABL and the T315I mutant were dis-
placed from HSP90 by the drug (Figure 6D). Thus, a decrease
in kinase activity is not necessary for HSP90 displacement.
Stabilization of the kinase fold, either in its active or inactive
conformation, is sufficient.BCR-ABL Mutations Modulating HSP90 Interaction
Affect Protein Stability
Our results with kinase inhibitors suggested that thermal stability
is a major determinant of HSP90::kinase interactions. The meta-
stable folds of Hsp90 chaperone clients make them difficult to
analyze in vitro. Indeed, only two proteins (oncogenic v-Src
and its cellular counterpart c-Src) have been specifically as-
sessed both for differences in HSP90 interaction in vivo and
differences in thermodynamic stability in vitro (Falsone et al.,
2004). This pair presents an extreme in terms of Hsp90 interac-
tions (very strong versus very weak client) and in terms of confor-
mational equilibrium (active, open conformation versus inactive,
closed conformation) (Falsone et al., 2004). To further investigate
the relationship between HSP90 association and thermody-
namic stability, we focused on two additional BCR-ABL variants,
both methionine-to-isoleucine substitutions, that had opposing
but relatively subtle effects on the BCR-ABL::HSP90 interaction.
The M244I mutation in the N-terminal lobe decreased Hsp90
interaction by about 50%; the M472I mutation in the C-terminal
lobe increased it 2-fold (Figure 6E).
We expressed both mutants and the wild-type Abl in bacteria
and purified them to homogeneity. The constructs contained Abl
residues 65-534, including the SH3, SH2 and kinase domains.
Importantly, due to the lack of an inhibitory myristoylation site
in the N terminus, recombinant Abl adopts an active conforma-
tion similar to that of the kinase domain in the context of BCR-
ABL fusion (Iacob et al., 2011). Both mutants had in vitro kinase
activities comparable to that of the wild-type kinase (data not
shown) and their secondary structure content, as measured by
circular dichroism spectroscopy was very similar (Figure S5C).
However, the thermal stability of the kinase constructs was
significantly different. The Tm of wild-type Abl was 41.5
C. For
the M472I mutant it was 38.0C and for the M244I mutant it
was 45.4C (Figure 6F). Thus, the increase and decrease in
HSP90 interactions for these mutants reflected differences in
the thermodynamic stability of their kinase folds. Taken together,
the breadth of our analyses reveal that thermodynamic stability,
not primary amino acid sequence, is a key determinant in the
association of kinase clients with HSP90.
DISCUSSION
High-throughput quantitative analysis of genetic interactions
in vivo, pioneered in the budding yeast, has greatly increased
our understanding of cellular circuitries (Costanzo et al., 2010).
LUMIER with BACON provides a method for revealing the phys-
ical interaction networks in a quantitative manner on a compa-
rable scale. We utilized the assay to quantitatively characterize
the in vivo interactions of HSP90 and CDC37 with the majority
of wild-type human kinases, transcription factors, and E3
ligases. HSP90 is known to play a key role in regulating cellular
circuitry and, together, the assayed proteins form the core of
that circuitry. The analysis uncovered interactions between
HSP90 and almost 400 client proteins, more than all previous
studies combined, considerably expanding our picture of this
essential chaperone’s function in human cells.
More importantly, this quantitative and systematic approach
allowed us to place HSP90 interactions into a broader contextCell 150, 987–1001, August 31, 2012 ª2012 Elsevier Inc. 997
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Figure 7. Model for HSP90::Kinase Interac-
tions
Kinase domains are in equilibrium between the
fully folded and HSP90-binding competent con-
formations. CDC37 cochaperone recognizes the
kinase fold and recruits kinases to HSP90. HSP90
binds the alternative kinase conformation and
assists the kinase in adopting the fully folded
conformation. Client kinases thus undergo re-
peated rounds of chaperoning, whereas nonclient
kinases are stable when fully folded. Binding of an
inhibitor to its target kinase increases the stability
of the kinase fold and thus decreases HSP90
interaction. HSP90 inhibitors block the loading of
the client to the chaperone, which leads to
aggregation of the partially unfolded kinase or
degradation by the ubiquitin-proteasome system.and uncover global principles that could not be established with
studies of individual clients, nor with previous high-throughput
approaches. First, theCDC37 cochaperone serves as an adaptor
andprovides specificity for protein kinases at the family level. Our
assay should allow the identification of adaptors for other typesof
fold, such as leucine-rich repeat proteins (Kadota et al., 2010) and
the b-propeller WD40 and Kelch domains (reported here).
Second, within the kinase family, Hsp90 clients are ultimately
distinguished from nonclients on the basis of their intrinsic
stability. Agents that stabilize a client kinase in either its active
or inactive conformation reduce HSP90 association, demon-
strating that HSP90 does not bind the kinase in either of its folded
states. We suggest that client kinases are unstable in their fully
folded forms, with a higher tendency to adopt a conformation
that HSP90 and CDC37 can recognize. Associations with
HSP90, then, would be determined by the equilibrium
between the fully folded and chaperone-susceptible conforma-
tions of each client. This conformational model can explain
why kinase::HSP90 interactions fall into a continuum spanning
over a 100-fold range, in contrast to the binary model of clients
and nonclients. In keeping with this interpretation of our high-
throughput analysis, in an electron microscopic analysis of a
particular client complex, HSP90/CDC37/CDK4, both lobes of
the CDK4 kinase are visible, clearly indicating that this client is
not in its tightly packed closed conformation (Vaughan et al.,
2006). As HSP90 client kinases undergo repeated rounds of
binding and release, inhibition of HSP90’s ATPase activity
prevents reloading of clients onto the chaperone (Krukenberg
et al., 2011). This redirects the clients to one of two alternative
fates: degradation or aggregation (Figure 7).
The client protein dissociation rates we observed in vivo
(T1/2 = 2–6 min) upon HSP90 inhibition were surprisingly close
to the ATP hydrolysis rate of HSP90 in vitro (Richter et al.,
2008). Moreover, although the strength of Hsp90’s associations998 Cell 150, 987–1001, August 31, 2012 ª2012 Elsevier Inc.with strong versus weak clients varied
over a 100-fold range, most clients dis-
sociated from HSP90 with very similar
kinetics. These observations imply that
the dominant determinants of HSP90
association are client-binding on-rates.How can our model be reconciled with the existing aC-b4
recognition loop model (Citri et al., 2006; Xu et al., 2005)? The
aC-b4 loop is located immediately adjacent to the kinase hinge
region that in many kinases is involved inmaintaining the inactive
conformation (Chen et al., 2007). In fact, the backbone atoms of
the aC-b4 loop in several kinases form hydrogen bonds with crit-
ical residues in the hinge. Loss of these hydrogen bonds leads
to ligand-independent kinase activation (Chen et al., 2007).
This network of stabilizing hydrogen bonds is conserved in
several tyrosine kinases, and mutations in the aC-b4 loop in
ERBB2 lead to activation of the kinase (Fan et al., 2008). Thus,
it is likely that mutations introduced in the loop increase the
flexibility of the hinge and lead to increased HSP90 interaction
due to structural destabilization, not through the introduction of
a new binding motif.
Our model accounts for a number of previous findings. First,
some kinases, such as c-Src and EGFR, associate transiently
with HSP90 during maturation, but the fully folded proteins do
not bind HSP90 (Xu et al., 1999, 2005). Second, some mutations
can decrease a kinase’s steady state association with HSP90
without having an effect on the transient association during
maturation. It has been suggested that the motif HSP90 recog-
nizes during posttranslational folding of kinases is distinct from
that recognized in mature proteins (Xu et al., 2005). Amore parsi-
monious explanation is that HSP90 binds on-pathway conforma-
tions. Kinases such as c-Src and EGFR access this conformation
during initial folding, but they are stable after reaching their
mature states. But strong client kinases repeatedly access the
Hsp90-susceptible conformation after their initial folding.
Parallels between Kinase and Steroid Hormone
Chaperoning
For 30 years, steroid hormone receptors have been the most
thoroughly studied class of HSP90 clients, and our current
mechanistic understanding of the chaperone is largely based on
detailed in vitro studies with steroid hormone receptors (SHRs)
(Picard, 2006). Although we find that transcription factors actu-
ally represent a minor fraction of HSP90 clients, our data present
striking parallels between the modes of kinase and SHR chaper-
oning. Consider the steps of progesterone receptor chaperoning
by HSP90: without progesterone, the receptor associates with
HSP90 through its ligand-binding domain. HSP90 aids the
ligand-binding domain in maintaining a conformation that is
competent to bind the ligand. Upon ligand binding, the receptor
dissociates from HSP90, translocates to the nucleus and regu-
lates target gene expression (Picard, 2006). The binding of a
kinase inhibitor stabilizes the kinase fold and shifts the equilib-
rium away from HSP90 as, presumably, would the binding of
ATP and the kinases’ physiological substrates. Might a common
HSP90 function be the modulation of ligand-binding clefts in
signal transducers, as previously suggested (Pratt et al., 2008)?
Notably, other HSP90 clients are also regulated by ligands. Argo-
naute proteins, which are involved in small RNA biogenesis,
require HSP90 for loading of the ligand, a small RNA duplex (Iwa-
saki et al., 2010). Similarly, inducible nitric oxide synthase (iNOS),
another HSP90 client, binds heme as a cofactor, and depletion of
heme increases HSP90::iNOS interaction (Ghosh et al., 2011).
HSP90 and the Evolution of Eukaryotic Kinomes
We have found that all kinase families have both client and non-
client kinases, indicating that HSP90 client proteins did not
evolve from a common client ancestor, or even a small number
of ancestors. Clients are not ‘‘chaperone-addicted’’ in an evolu-
tionary sense, but rapidly evolve into and out of dependence on
HSP90. If kinases can rapidly evolve away from chaperone-
assisted folding, why haven’t they generally done so? One
explanation is that we are simply catching them in the act of
making such transitions. But a more interesting possibility is
that some kinases specifically exploit association with the
HSP90 machinery as a means of regulation. Compared to other
regulatory proteins, kinase activity is controlled by a particularly
rich spectrum of mechanisms and these protein undergo exten-
sive structural rearrangements upon activation (Taylor and
Kornev, 2010). The inherent instability of some kinases, which
tunes their interaction with Hsp90, may well be employed as a
mechanism to ensure the fidelity of regulatory cascades. Such
instability could affect the regulation of signal transduction path-
ways with more immediacy, and be more easily tuned to
changing environmental conditions, than mechanisms acting at
the level of transcription, translation or degradation. Indeed,
because HSP90’s chaperone activity is ATP-dependent and its
affinity for ATP is relatively low, HSP90 interactions could
provide ameans to sense energy states and coordinate an entire
network of kinases with the ATP balance in the cell.
On a longer timescale, considering the role of HSP90 in the
evolution of complex traits (Jarosz and Lindquist, 2010; Queitsch
et al., 2002; Rutherford and Lindquist, 1998; Specchia et al.,
2010), the chaperone has likely facilitated the remarkable diver-
sification of the kinase family. Eukaryotic genomes encode
hundreds of different kinases, but the exact composition of the
kinome varies strikingly between phyla (Manning et al., 2011).
In yeast, CDC37 is required for the stability of most kinases(Mandal et al., 2007). Together with our observation that
CDC37 is a universal kinase cochaperone in human cells, this
suggests that HSP90 and CDC37 have together sculpted the
evolution of kinases for billions of years. As the evolution of novel
functions occurs usually through destabilizing mutations, HSP90
may have acted as an evolutionary ‘‘backbone,’’ allowing
kinases to evolve through a relaxed mutational landscape. The
facilitation of kinome evolution by HSP90 could partly explain
why kinases have emerged as some of the most diverse drivers
of biological complexity.
EXPERIMENTAL PROCEDURES
LUMIER with BACON
3 3 FLAG-tagged bait proteins were transfected into stable 293T cell line in
96-well format with polyethylemine (PEI). Two days after transfection, cells
were washed in 1 3 PBS and lysed in ice-cold HENG buffer (50 mM
HEPES-KOH [pH 7.9], 150 mMNaCl, 20 mMNa2MoO4, 2 mM EDTA, 5% glyc-
erol, 0.5% Triton X-100). The combination of low temperature, the absence of
ATP and the presence of molybdate freezes the chaperone cycle and stabi-
lizes HSP90::client interactions. The lysate was transferred to 384-well plates
coated with anti-FLAG M2 antibody (Sigma-Aldrich). Plates were incubated
in cold room for 3 hr, after which plates were washed with the lysis buffer using
an automated plate washer. Luminescence in each well was measured with
an Envision plate reader using Gaussia FLEX luciferase kit (New England
Biolabs). After luminescence measurement, HRP-conjugated anti-FLAG
antibody in ELISA buffer (13 PBS, 2% goat serum, 5% Tween 20) was added
to wells. Plates were washed in 13 PBS/0.05% Tween 20 with a plate washer
and ELISA signal was detected with 3,3’,5,5’-tetramethylbenzidine (TMB)
substrate.
Computational Analysis of HSP90 Clients
To identify significantly covarying residues, we used mutual information anal-
ysis, OMES covariance, SCA covariance, andMcBasc as implemented in Java
(Fodor and Aldrich, 2004). All programs were used with their default settings.
Only strong clients and nonclients were considered in the analysis and loops
were excluded due to poor alignment confidence. To evaluate the significance
of the scores from each covariance method, we performed a randomization
analysis with 10,000 permutations. We sampled without replacement the class
labels for all sequences and ran all algorithms on the newly generated random-
ized data sets to generate 10,000 scores for each algorithm. We generated an
empirical p value for every residue from each algorithm. We used a p value
cutoff of 0.01 for marking a residue as significant and selected for further anal-
ysis only the residues identified as significant by all algorithms.
Nonparametric statistical analyses were applied unless specified otherwise.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures
five figures, and one table, and can be found with this article online at http://
dx.doi.org/10.1016/j.cell.2012.06.047.
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